Consort Medical plc announced audited consolidated financial results for the year ended 30 April 2018. For the year, on underlying basis, the company reported PBT of £38.2 million, EBIT of $42.7 million, adjusted basic EPS of £64.5 pence on revenue of £311.1 million against PBT of £35.6 million, EBIT of $40.0 million, adjusted basic EPS of £65.1 pence on revenue of £294.0 million for the last year. Net debt was at £95.5 after investments in equipment and streamlining the business. Operating profit was £21.8 million against £26.3 million for the last year. Profit before tax was £17.3 million against £21.9 million for the last year. Profit for the financial year was £16.1 million against £22.6 million for the last year. Adjusted diluted earnings per ordinary share was 63.9 pence against 64.4 pence for the last year. Net cash inflow from operating activities was £32.4 million against £40.7 million for the last year. Purchases of property, plant and equipment was £20.9 million against £18.0 million for the last year. Purchases of intangible assets was £1.3 million against £0.1 million for the last year. Group revenue was up 5.8%. EBIT up 6.8%. PBT was up 7.3%. Consort has again delivered revenue and profit growth with 5.8% higher sales and a 6.8% increase in EBIT.

For the year, on statutory basis, the company reported PBT of £17.3 million and basic EPS of £32.9 pence against PBT of £21.9 million and basic EPS of £46.2 pence for the last year.

The company announced that the Board is confident of Consort's future prospects supported by a robust financial position and a strong development pipeline. The Board's expectations for the current financial year 2018 remain unchanged.